A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma - Phase 2 Study of V937 Plus Pembrolizumab

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc0 sites85 target enrollmentOctober 30, 2019

ConditionsAdvanced/metastatic melanoma MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864 Therapeutic area: Diseases [C] - Cancer [C04]

DrugsKEYTRUDA (pembrolizumab, MK-3475)

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Advanced/metastatic melanoma
Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Enrollment: 85
Status: Active, not recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

October 30, 2019

End Date

July 12, 2023

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc

Eligibility Criteria

Inclusion Criteria

•1\. Has histologically or cytologically confirmed diagnosis of advanced/metastatic melanoma
•2\. Has Stage III (unresectable) or Stage IV melanoma
•3\. Participants must be naive to anti\-PD\-(L)1 treatment, TVEC and other oncolytic viruses
•4\. Has 2 lesions as defined below:
•Lesion 1: Has at least 1 cutaneous or subcutaneous lesion amenable to IT injection and biopsy. The injectable lesion must be measurable and meet 1 of the following criteria (per RECIST 1\.1 for solid tumors):
•\- A cutaneous or subcutaneous lesion \= 1 cm in longest diameter for solid tumors, or \= 1\.5 cm in short axis for a nodal lesion in participants with solid tumor. The longest diameter for an injectable lesion must be \= 10 cm for both solid tumors and nodal lesions in participants with solid tumor
•\- Multiple coalescing, superficial lesions that in aggregate have a longest diameter of \= 1 cm and \= 10 cm
•Lesion 2: Have at least 1 measurable, distant and/or discrete noninjected lesion that is amenable to biopsy via visual inspection or amenable to biopsy via image guidance, such as ultrasound or computed tomography (CT)/magnetic resonance imaging (MRI). The lesion must be measurable and meet 1 of the above mentioned criteria per RECIST 1\.1
•5\. Has a a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
•6\. Demonstrates adequate organ function

Exclusion Criteria

•1\.Has had chemotherapy, definitive radiation, or biological cancer therapy or an investigational agent or investigational device within 4 weeks (2 weeks for palliative radiation) prior to the first dose of study intervention or has not recovered to Common Terminology Criteria for Adverse Events Grade 1 or better (except alopecia) from any AEs that were due to cancer therapeutics administered more than 4 weeks earlier. If participant received major surgery or radiation therapy of\>30 Gy, they must have recovered from the toxicity and/or complications from the intervention. Participants receiving ongoing replacement hormone therapy for endocrine immune\-related AEs will not be excluded from participation in this study
•2\.Has ocular melanoma
•3\.Has radiographic evidence of major blood vessel invasion/infiltration. The degree of tumor invasion/infiltration of major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis
•4\.Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
•5\.Has an active autoimmune disease that has required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy. Replacement therapy, such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, is not considered a form of systemic treatment and is allowed
•6\.HIV\-infected participants with a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease
•7\.Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study
•8\.Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years
•9\. Has not fully recovered from any effects of major surgery without significant detectable infection. Surgeries that required general anesthesia must be completed at least 2 weeks before first study intervention administration. Surgery requiring regional/epidural anesthesia must be completed at least 72 hours before first study intervention administration and participants should be recovered
•10\.Clinically significant cardiovascular disease:cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication